Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

BACKGROUND: We report the clinical activity, safety, and identification of a predictive biomarker for bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFβRII (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1, in patients with advanced tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Spira, Alexander, Awada, Ahmad, Isambert, Nicolas, Lorente, David, Penel, Nicolas, Zhang, Yue, Ojalvo, Laureen S., Hicking, Christine, Rolfe, P. Alexander, Ihling, Christian, Dussault, Isabelle, Locke, George, Borel, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773992/
https://www.ncbi.nlm.nih.gov/pubmed/36568239
http://dx.doi.org/10.3389/fonc.2022.981940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773992/
https://www.ncbi.nlm.nih.gov/pubmed/36568239
http://dx.doi.org/10.3389/fonc.2022.981940

Ejemplares similares